How long can a patient with diabetic neuropathy safely continue pregabalin 75 mg?

Duration of Pregabalin 75 mg for Diabetic Neuropathy

Pregabalin 75 mg can be taken long-term for diabetic neuropathy, with safety data supporting continuous use for at least 2 years, though this dose is below the therapeutic range and should typically be increased to 150-600 mg/day for optimal pain relief. 1

Evidence for Long-Term Use

FDA-approved safety data demonstrates that pregabalin can be used safely for extended periods:

• Over 10,000 patients received pregabalin during premarketing trials, with approximately 5,000 treated for 6 months or more, over 3,100 for 1 year or longer, and over 1,400 for at least 2 years 1
• A 52-week open-label study in Japanese patients with painful diabetic peripheral neuropathy (DPN) showed sustained analgesic effects throughout the treatment period, with no new safety concerns emerging from long-term administration 2
• Long-term efficacy was maintained with continued pain relief measured by the McGill Pain Questionnaire, visual analog scale, and present pain intensity scores 2

Critical Dosing Consideration

Your current dose of 75 mg/day is subtherapeutic:

• The FDA-approved starting dose for diabetic neuropathy is 150 mg/day (50 mg three times daily), which may be increased to 300 mg/day within one week based on efficacy and tolerability 1
• Patients not experiencing sufficient pain relief after 2-4 weeks at 300 mg/day who tolerate the medication may be increased to 600 mg/day 1
• The recommended therapeutic dose range is 150-600 mg/day in divided doses 3
• Pooled analysis data shows number needed to treat (NNT) of 4.04 for 600 mg/day and 5.99 for 300 mg/day, demonstrating dose-dependent efficacy 3

Cardiovascular Safety Concerns with Long-Term Use

Recent evidence raises important cardiovascular concerns that must be weighed against benefits:

• A large retrospective cohort study (210,064 patients) found that long-term pregabalin use in diabetic neuropathy patients was associated with increased 5-year risk of cardiovascular events 4
• Highest risks included deep venous thrombosis (HR: 1.57), peripheral vascular disease (HR: 1.35), myocardial infarction (HR: 1.29), pulmonary embolism (HR: 1.28), stroke (HR: 1.26), and heart failure (HR: 1.2) 4
• Even short-term (3-month) use showed associations with deep venous thrombosis and peripheral vascular disease 4
• These cardiovascular risks should be considered alongside efficacy and tolerability when prescribing long-term 4

Common Adverse Effects During Long-Term Treatment

Most adverse events occur early and are generally manageable:

• Dizziness and somnolence are most common, with highest incidence in the first week of treatment, followed by steady decline in new cases 5
• Other frequent adverse effects include peripheral edema, weight gain, headache, and confusion 3
• Weight gain typically emerges 6-8 weeks after treatment initiation and requires regular monitoring 5
• Adverse effects may be more severe in older individuals but can be attenuated with lower starting doses and gradual titration 3
• Most adverse events are mild to moderate in intensity and many resolve within the first month of treatment 2, 5

Practical Management Algorithm

For continuing pregabalin therapy:

1. If pain control is inadequate at 75 mg/day: Increase to 150 mg/day (50 mg TID) immediately, as 75 mg is below the therapeutic threshold 1

2. After 1 week at 150 mg/day: If tolerated but pain relief insufficient, increase to 300 mg/day 1

3. After 2-4 weeks at 300 mg/day: If pain relief remains inadequate and medication is well-tolerated, consider increasing to 600 mg/day 1

4. Monitor regularly for:

   • Cardiovascular symptoms (chest pain, shortness of breath, leg swelling) given increased long-term cardiovascular risks 4
   • Weight gain starting at 6-8 weeks 5
   • Dizziness and somnolence, particularly in first week after dose increases 5
   • Signs of peripheral edema 3

5. Adjust for renal impairment: Pregabalin is eliminated primarily by renal excretion; dose adjustment is mandatory in patients with reduced renal function 1

Important Caveats

• Pregabalin provides only symptomatic pain relief and does not alter the natural history of diabetic peripheral neuropathy, which involves progressive nerve fiber loss 3
• Approximately 30% of patients may discontinue long-term use due to adverse effects 6
• The medication is classified as Schedule V controlled substance due to potential for abuse and dependence 7
• Discontinuation rates in clinical trials were 9% for pregabalin versus 4% for placebo, primarily due to dizziness and somnolence 1